Steven Cohen Kura Oncology, Inc. Transaction History

Point72 Asset Management, L.P.

$36.6 Billion
Q3 2024

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 189,103 shares of KURA stock, worth $1.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

189,103

Holding current value

$1.7 Million

% of portfolio

0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$18.57 - $23.23 $3.51 Million - $4.39 Million	189,103 New	189,103 $3.7 Million
Q1 2023 May 15, 2023	BUY	$10.71 - $14.6 $122,393 - $166,848	11,428 New	11,428 $139,000
Q4 2020 Feb 16, 2021	SELL	$29.0 - $41.62 $4.64 Million - $6.66 Million	-159,936 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$16.3 - $30.64 $296,073 - $556,544	-18,164 Reduced 10.2%	159,936 $4.9 Million
Q2 2020 Aug 14, 2020	BUY	$7.95 - $18.81 $1.42 Million - $3.35 Million	178,100 New	178,100 $2.9 Million
Q1 2020 May 15, 2020	SELL	$6.45 - $14.04 $1.03 Million - $2.24 Million	-159,612 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$12.97 - $15.94 $2.07 Million - $2.54 Million	159,612 New	159,612 $2.2 Million
Q4 2018 Feb 14, 2019	SELL	$10.6 - $17.49 $4.01 Million - $6.61 Million	-377,952 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$16.65 - $21.85 $4.09 Million - $5.36 Million	245,406 Added 185.15%	377,952 $6.61 Million
Q2 2018 Aug 14, 2018	BUY	$14.8 - $18.8 $1.96 Million - $2.49 Million	132,546 New	132,546 $2.41 Million
Q1 2018 May 15, 2018	SELL	$14.5 - $23.4 $2.51 Million - $4.05 Million	-173,200 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$13.5 - $16.65 $2.34 Million - $2.88 Million	173,200	173,200 $2.65 Million

Others Institutions Holding KURA

# of Institutions

185

Shares Held

81.8M

Call Options Held

42.1K

Put Options Held

34K

View Full List

About Kura Oncology, Inc.

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $603M
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

More about KURA

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account